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The authors report the case of a chronic myeloid leukemia (CML) patient submitted to allogenic bone marrow  transplantation,
who had probably never entered complete remission. The disease was reactivated as a granulocytic sarcoma, next to a platinum
plate installed to correct a tibia fracture 11 years earlier. Its final event was a myeloid Ph1+ blastic crisis that was unsuccessfully
treated with high doses of sc interferon and citarabine.
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INTRODUCTION
Granulocytic sarcoma (GS) is an extramedullarytumor originally called chloroma(1) due to itsgreen-colored aspect. It is frequently reported in
young patients with acute myeloid leukemia (AML) and
chronic myeloid leukemia (CML). It mainly involves the
periosteum of skull bones, sternum, vertebrae, and less
frequently the soft tissues of the chest wall, arms, skin,
kidney, gut, ovary, lung and lymph nodes(1). Its
pathogenesis is unknown, although there is a hypothesis
that traumatic extravasation and proliferation of mitotically
competent leukemic cells in normal tissues could explain
its appearance(1). Isolated GS seems to be a rare disease,
particularly after marrow transplantation. After review, we
found only one previous report of cutaneous GS after
autologous bone marrow transplantation for acute myeloid
leukemia (AML)(1).
CASE REPORT
A 26 year-old female patient was diagnosed as having
Ph1+ CML in 1992, which was successfully controlled
with hydroxyurea. She had a history of a surgery in the
left tibia after an accident 11 years earlier.
In August 1993, she was treated with bussulfan and
cyclophosphamide as a  conditioning regimen to kill her
normal and malignant CML clones, and received bone
marrow cells from her brother, an identical HLA donor
(locus A,B and DR). Graft versus host disease (GVHD)
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prophylaxis was necessary to avoid a reaction of the
donor’s immune system against host tissues (such as skin,
gut, liver) and, in this case, it consisted of cyclosporin
plus short term methotrexate. Prophylaxis of
cytomegalovirus infection was performed using acyclovir
until engraftment and thereafter with gancyclovir. As a
complement for infection and GVHD prophylaxis, IV
immunoglobulin was used from day -6 to day +100. During
the neutropenic period, she received a 21-day imipenem
course. GM-CSF was used to stimulate  bone marrow
engraftment from day +1 to +18, when the granulocyte
count reached 1500/mm3.
On day +220 post transplantation, and exactly 10
days after the end of immunosuppression, swelling and
erythema were observed in the left knee simultaneously
with local pain and immobilization. Several synovial fluid
aspirations showed low lymphocyte counts and sterile
cultures. Local X-ray, ultrasonography, double phase Tc-
scintillography and magnetic resonance images were
suggestive of distal femur osteomyelitis. She was treated
with vancomycin for 35 days without success. At that time
the Ph1 chromosome was present in less than 10% of the
analyzed cells, and also bcr-abl rearrangement was positive
by RT-PCR, showing persistence of minimal residual
disease but not necessarily MT failure (Fig. 1).
At day +276 she complained of  pain and enlargement
of  the left knee. She was submitted to a synovial biopsy
which was suggestive of granulocytic sarcoma.
Immunohistochemical reactions were positive for lysozyme
and CD 45 and negative for B and T antigens, confirming
the diagnosis of GS (Fig. 2). At this time, Tc-bone
scintillography scanning of the skeleton was normal. She
received irradiation of 5000 cGy on her left knee and was
maintained under observation for 5 months, until the onset
of a 1.5 cm node in her right breast  and a large tumor in the
right iliac bone. The biopsies of both lesions showed the
same morphology and reactions previously described.
Fifteen months post marrow transplantation, Ph1+ acute
myeloid leukemia was fully developed. She was treated with
alpha interferon and citarabine, and peripheral blast cell
count and tumoral mass decreased within 25 days. As a
complication of multiple bone GS, she evolved to
hypercalcemia (calcium level: 1.79 mMol/l; PTH level: 9pg/
ml), which was treated with vigorous hydration, prednisone
and pamidronate. Thirty five days after the diagnosis of
acute leukemia, she died due to a sudden febrile interstitial
pneumonia. Marrow and WBC counts were compatible with
hypoplasia post- chemotherapy. Post mortem examination
was not allowed by her relatives.
DISCUSSION
CML is a malignant disease with a fatal outcome
after a blast crisis within approximately three years. HLA
related bone marrow transplantation represents the only
chance of cure for  patients younger than 40 years old,
especially if performed during the first year after the
diagnosis(2). Thus, bone marrow transplantation was
indicated for our patient.
Light to moderate GVHD is a desirable effect in
marrow transplantation to avoid clinical, cytogenetic and
even molecular relapse. Disease control is the result of an
interaction between donor immune system cells and the
host CML clone(3). Several observations have demonstrated
higher relapse rates in syngenic transplantations and in T
cell depleted allografts. Patients with acute and chronic
GVHD have a lower relapse rate compared to individuals
that do not suffer from this complication, and finally,
relapsed patients can be successfully treated with leukocyte
infusions obtained by cytopheresis from the original donor.
In the present case, the long period of  IV immunoglobulin
infusion to prevent infections and GVHD(4,5) resulted in
no evidence of GVHD, which probably contributed to the
absence of the desirable graft-versus-leukemia effect.
Therefore, IV immunoglobulin is preferentially indicated
1. a month before MT - 46, XX, t(9;22) 100%.
2. day +21, 46, XY 71.5%,  46, XX, t(9;22) 28.5% .
3. day +68, sustained engraftment - 46, XY 75%,  46, XX, t(9;22) 25%.
4. day +98, sustained engraftment- 46, XY 65%, 46, XX 5% e 46, XX,
t(9;22) 30%
5. day +214, clinical evidence of GS - 46, XY 89.5%e 46, XX, t(9;22) 10.5%
6. day +473, AML episode - 46, XY 31.5% e 46, XX, t(9;22) 68.5%.
Figure 1 - Ph1 chromosome evolution in bone marrow samples
after MT.
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when some grade of GVHD is expected, particularly for
unrelated donors and non-identical siblings.
The rare event described here was difficult to identify
by conventional image methods and only the open biopsy
led to the correct diagnosis. The patient had molecular
evidence of minimal residual disease when the inflammatory
process started and the Ph1 clone could be detected by a
cytogenetic relapse later.
In the present case, GS appeared as a late
complication of marrow transplantation next to a platinum
plate installed after trauma many years earlier. We believe
that there was some grade of traumatic fibrosis next to the
plate which led to inadequate blood supply for
chemotherapy in this area. So, an unanswered question
remained: could the previous status of the proximal tibia
and knee have been a barrier against the destruction of
leukemic cells at these sites?
Unfortunately, she was not in a clinical condition to
be submitted to a second MT, but leukopheresis from the
donor’s marrow could have been a good alternative
procedure at that time. The option of treatment with
interferon after the AML event was based on some
evidence of clinical improvement under such a regimen
in CML patients who relapsed after MT(3).
About 30 cases of hypercalcemia associated with
CML have already been documented(6). As was observed
in the present case, hypercalcemia signifies bad prognosis.
The pathogenesis of hypercalcemia in CML is still unclear,
but generally it is  attributed to bone invasion and
destruction by leukemic cells. Standard therapy for
hypercalcemia (hydration followed by forced diuresis,
corticosteroids or calcitonin) may be not successful. It is
reported that effective treatment requires administration
of pamidronate, which promotes a relatively selective
inhibition of osteoclast activity or chemotherapy directed
to leukemia(6), as we could observe in this case.
We suggest that many factors such as 1) the absence
of any manifestation of chronic GVHD, 2) the use of high
and extended IV immunoglobulin doses, 3) post traumatic
tibia fibrosis and 4) the persistence of CML clones after
marrow transplantation could have contributed to the
outbreak of GS and further AML. Unfortunately, as
demonstrated by her clinical course, the CML clones had
never been eradicated by the marrow transplantation.
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RESUMO
Os autores relatam um caso de leucemia mielóide crônica tratada com transplante alogênico de medula óssea e que
provavelmente nunca entrou em remissão completa da doença. A paciente apresentou reativação como sarcoma granulocítico
junto a uma placa de platina instalada há 11 anos, após fratura de tíbia. Descrevem também outras manifestações de recidiva
e término em crise blástica mielóide Ph1+ sem sucesso tratada com altas doses de interferon se e citarabina.
